Company Profile Search

Number of investor members

  212

Search for Member

Advanced Search

Immuron - 30 day Poll

Possible Announcements

View Possible Upcoming Company Announcements

Event details

Pharmaxis Phase III conference call

Description:
Pharmaxis Ltd (PXS) expects to complete its analysis and announce the results of its second
international Phase III clinical trial of Bronchitol in patients with cystic fibrosis prior to the end
of today, 22 June 2010. The announcement will have the effect of lifting the current trading
halt over the company’s shares.
The company will hold an investor teleconference at 5.00pm today to discuss the results.
Telephone access (toll free) details are below:
 Australia: 1800 838 758
 USA/Canada: 866 746 2596
 UK: 0800 376 8339
 NZ: 0800 446 958
 Switzerland: 0800 001 230
 Singapore: 800 120 4406
 Hong Kong: 800 962 283
Online access: services.choruscall.com/links/pharmaxis1 00622.html
A recording of the conference will be available on the Pharmaxis website home page by
noon Wednesday 23 June. 
Location:
Conference call 
Starts on:
22/06/2010 17:00
Created by:
Jason

Comments


Terms & Rules

As per ASIC Regulatory Guide 162: All investment tips and comments appearing on this website (Poll results, BLOGS & discussion forums) are submitted by the general public who are not licensed financial advisors. None of the information on this website is financial or investment advice, you should seek independent financial or investment advice by a licensed financial or investment advisor before entering into any position of financial risk. Before using this website, you must agree to the BioInvesting.com.au Terms Of Use

Before using this Biomedical Investing website

OR